SREBF2 and lung cancer: Similar results were observed in TCGA lung cancer database (Supplementary Fig. 5C) and validated in control cells (ScrKO) treated with or without recombinant NPY protein (100 nM), in the presence or absence of the ERK5 inhibitor (100 nM), compared to untreated or Y5rKO cancer cells (Fig. 4G-H), providing further evidence for the regulatory role of NPY in modulating the ERK5/SREBP2 signaling pathway.